Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Fausel

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Hospital Pharmacy|June 30, 2016
Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology PharmacyLisa M Hess, Frank N Cinfio, Stewart Wetmore, et al.
The Oncologist|January 18, 2007
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21Attaya Suvannasankha, Christopher Fausel, Beth E Juliar, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Hospital Pharmacy|June 30, 2016
Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology PharmacyLisa M Hess, Frank N Cinfio, Stewart Wetmore, et al.
The Oncologist|January 18, 2007
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21Attaya Suvannasankha, Christopher Fausel, Beth E Juliar, et al.
Pageof 2